U.S. Markets closed

How Healthcare's Changed in the Past 25 Years, Plus What's Next

Todd Campbell, The Motley Fool

A tidal wave of discovery that's resulting in game-changing gene therapies was sparked by a $3 billion project to sequence the human genome in the 1990s. Was the Human Genome Project the most important research program of the past 25 years?

In this episode of Industry Focus: Healthcare, host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss the significance of the Human Genome Project, how Illumina's (NASDAQ: ILMN) driving gene-sequencing costs lower, and the role genetics will play in the future of medicine. 

Also, the two consider how the healthcare we get in a doctor's office has changed since the 1990s, and how technologies such as Teladoc's (NYSE: TDOC) telehealth products might help bridge the growing gap between healthcare supply and demand. 

A full transcript follows the video.

More From The Motley Fool

This video was recorded on June 27, 2018.

Kristine Harjes: Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day. Today is June 27th, and this is the Healthcare show. I'm your host, Kristine Harjes, and healthcare specialist Todd Campbell is calling into the studio here in Alexandria, Virginia.

We're continuing our 25 Years theme week today in celebration of The Motley Fool's 25th anniversary, which is coming up this Saturday. In this episode, Todd and I will reflect on what healthcare looked like 25 years ago, and also where we see it going over the next 25 years. Ready to dive in, Todd?

Todd Campbell: I am!

Harjes: Let's hop in our time machine and go back to 1993 and take a trip to the doctor's office. Todd, you will remember what that was like a lot more than I will, given my age at the time. What stands out in your memory?

Campbell: I was about one year out of college at the time, so I didn't have to go too often, luckily. I suppose I would have gotten into my Acura Integra -- [laughs] getting in the way back machine, right -- and I would have gone to my doctor's office. If you look back, thinking about what it was like going to the doctor back then, one of the things that jumps out at me, and it may jump out to other listeners who are my age or up, maybe just the perception that we have that when we walked into a doctor's office all those years ago, the doctor actually knew who we were, before they had to pull up a chart on the computer when they walked into the office. 

That could be a misperception. Memory tends to bend things in weird ways as we get a little bit older. But, I felt that assistants weren't doing as much of the work in the actual office. You waited in the waiting room, just like you would today, for a relatively long period of time, and then you would go into the office. But I feel like it was the doctor who was doing things like blood pressure testing and asking some of these basic questions that have now been handed off to assistants. 

I think you see that not just in primary care, but you also see that in other parts of healthcare, like in dental. I don't know how often you see your dentist, Kristine, I go a few times a year. Most of the time that I spend in the dentist's chair, I'm talking with my hygienist, not my dentist. I feel like there are a lot of reasons for that. I'm sure we're going to get into it. But it definitely feels to me like, over time, doctors have become more time-strapped. That could be one of the biggest trends or changes over the last 25 years.

Harjes: I'm not sure if it's because there are fewer doctors out there now, or if there's just a greater demand for healthcare, but it certainly seems like that's the case. If you just look at the demographics of our entire society, people are getting older, they're living longer, a lot of diseases that used to be a death sentence have become more manageable, to the point where they're chronic conditions. That requires a lot more healthcare. It definitely does seem to me to be the case that, when we look toward the next 25 years, we're going to need to find a way to increase the supply of healthcare, whether that's through adding more doctors, or hopefully also using clever tech and innovation to better be able to meet that rising demand.

Campbell: To your point, Kristine, I went back and I looked at it, because I wanted to get some data to put this in context for our listeners. One of the things that I found is, back in 1993 -- when the Gardners were just getting started on their Foolish journey -- the total number of doctor visits that were performed was about 717 million. Between 1993 and 2010, that climbed by almost 40%. 

Now, you would assume that some of that is going to be because your population is getting bigger, right? But the population only increased by about 19% in the period. You have a situation where not only are people living longer, etc., but you also have this scenario playing out where more people were seeing the doctor more frequently, I think climbing from 2.7 to 3.2 visits per year. 

And you're right. This is really taxing the supply of doctors. I think we've spent a lot of resources and time and policy trying to figure out how to handle the increased demand, make healthcare accessible to everyone. Maybe we need to start spending a lot more time on trying to figure out how to make sure there are enough doctors, nurse practitioners, and physicians' assistants out there to serve everyone who needs the care.

Harjes: It does seem like there's a pretty obvious need here for some sort of solution. What stands out to me when I think about what going to the doctor was like 25 years ago was how little has changed about the entire experience. I get the impression that part of the reason that so many young people are reluctant to go to the doctor is because of how antiquated the entire system is. We're used to technology meeting us at the level that we want to be at in so many areas of our lives -- I can book my fitness classes online, but I can't book my annual checkup online with my doctor. Facebook seems like it knows everything about me, but then, when I go into a doctor's office, I still have to fill out my date of birth, and all these other very basic facts of my personal information, on physical pieces of paper! 

Look at consumer goods, too, for example. When I want to buy my paper towels or anything, I can very easily price shop. I can go online, and I can compare prices from place to place, and get a very easy quote. You can't do that for medical services and for medicines themselves. It really does seem like, in all of the other sectors, these pain points have been greatly diminished, if not completely eliminated, except for in healthcare.

When I look at the changes that could be on the way for the next 25 years in healthcare, I think the best thing we can do is look to other sectors for a hint of, how exactly will the new trends take place, and how will other sectors handle the transition to an advancement, before it makes its way over to the seemingly much slower healthcare sector?

Campbell: Healthcare does move more slowly. There's no getting around that. I think one of the main drivers, possibly, of some of the changes and the disruption that we've seen over the last decade or so has been forced by regulatory change. I remember the HITECH Act and some of these things we've talked on the show about before, trying to encourage, with carrots and sticks, practices to go out and actually institute some of this technology.

Again, there's that old saying -- we can do it fast, we can do it well, we can do it cheap; pick two. When it comes to healthcare, you're talking about a doctor-patient relationship where that's where the focus should be. A lot of what technology does is aimed at streamlining, or potentially coming at odds, with increasing the amount of time that you spend with your patients on coming up with real solutions. I think there's a dynamic there at play that forces a slower adoption rate of some of these things, because people want to push back and say, "No, I want to be able to have that close interaction with my patient."

I think, ultimately, though, -- and, Kristine, it sounds like you're going to agree with me -- you're going to have to approach these kinds of innovations if you want to be able to handle the demand that we're going to see from patients. People are living longer, things are happening now that are turning diseases that were once death sentences into chronic diseases -- all of that is going to increase demand. Trying to figure out the way to handle all that demand is going to involve all sorts of different things.

One of the things that we've seen over the course of the last few years, Kristine, is the consolidation across the industry. You see a lot of private practices that are banding together and becoming a part of hospital networks, because the hospital networks will say, "We'll take over the administrative burden of that, and that way, that frees you to still visit with your patients." But at the same time, these are now viewed as profit centers, because of all the complexity that's associated with the industry and the way payments are generated. The hospital systems are saying, now, "Well, you need to schedule a patient every 11 minutes instead of every 15 minutes." That's creating so many different stressors throughout the system and the way healthcare is provided to Americans.

Harjes: You're right that there is this tension between, how can we automate things and make them more efficient and, how can we keep things high-touch and a good experience for the person? I want to go back to the reluctance that you were talking about, where people don't want to spend more time with a computer as opposed to their doctor. 

I don't think that's something that's unique to the healthcare system. You saw some reluctance, say, with the rise of e-commerce, where people were like, "No, I don't want to buy my clothes from Amazon. I want to go in the store and touch them and try them on." But, slowly but surely, people were won over by the convenience of this easier, simpler, online interaction. 

I think that we're seeing that unfold in healthcare, specifically with telehealth. We've talked a little bit about a company called Teladoc on this show. I think that this is something that will be a trend that really takes prominence, not even in 25 years, but maybe over the next five or so years. More and more employers are offering insurance plans that give you access to telehealth. I think people are starting to recognize that there are so many reasons why you would prefer a telehealth visit over actually having to go into a medical office.

Campbell: Especially if you're sick. If you're sick, you're saying, the last thing I want to do is go sit in an office and cough over everyone, and wait 15-20 minutes, and then get there and have a bunch of questions asked, and then my doctor comes in 15-20 minutes later. It's an hour, an hour and a half, before you actually get a prescription to take to the pharmacy. 

I think there are a lot of advantages that come with telehealth. It's on-demand. You mentioned a lot of employers. I think it's like 90% of large employers now offer some form of telehealth service. Listeners, if you work for a big company, you probably have access to this and you just may not know about it. I think the most recent statistics show that only 3% of employees actually take advantage of telehealth. 

My expectation, though, Kristine, would be that, as millennials represent an increasingly larger percentage of the workforce, their willingness to accept and adopt technology throughout their entire life, they're going to be the big drivers, as opposed to the adoption of telemedicine or telehealth. That would be, potentially, huge for a company like Teladoc. They say that their addressable patient market is something like $57 billion. I think last year, their sales were only $233 million. So, there's a tremendous opportunity for time-saving solutions like that.

I also, Kristine, think another one of these solutions could be increasing use of virtual reality-type devices, which can obviously help on the supply end, by training more doctors and more healthcare providers, but can also help patients by providing them with greater insight into different healthcare issues, and other technologies and medical devices. We've talked in the past about diabetes and some of the things that are occurring in diabetes, with the artificial pancreas, and different things that are allowing us to better monitor and track our disease, such as healthcare wearables. All of those things are providing so much information that I think will be used in exciting ways to maybe automate a lot of the healthcare that we're provided. And I don't mean that in a bad way. I mean, say, taking over a huge population of data and being able to find best practices that can just be rolled out very automatically and more efficiently to have better outcomes across the entire population.

Harjes: The broader trend that you're speaking to here is using tech to assist human decision-making and execution. It's something that, again, we see in other sectors. For example, think about self-driving cars. Machines are already helping humans drive pretty prominently with semi-autonomous vehicles, with features like lane assist. 

There's the healthcare equivalent. The one that comes to mind for me is in robotic surgery. Intuitive Surgical has their da Vinci surgical Systems, which help surgeons perform their surgeries better. Of course, this leads to better outcomes for the patients and shorter stays in hospitals. Again, this is taking that burden of demand off of the healthcare system little by little by harnessing technology.

Another one that I want to emphasize is artificial intelligence. Todd, you talked a little bit about making better use of data. I think that's huge. I really want to emphasize that there are so many applications of AI in healthcare. The one I'm most excited about is in diagnostics, and using better data, better information, and harnessing everything that computers can do now, to make better diagnoses. If you think about how many false positives occur across a bunch of different indications, I feel like there's a huge opportunity there to bring those numbers down and be more precise. Fields in radiology and dermatology, I could see ophthalmology, all of these, are really ripe for layering in machine learning, deep learning, and AI power, to be able to drive efficiencies.

Campbell: It's almost like a trend toward predictive healthcare, taking it one step earlier. It's not just preventative, it's predictive, where you're able to take a look at some of these insights into DNA or whatever and be able to come to some decisions early on about what kind of health crises we may face over our lifetimes, and then be able to intervene before we even suffer any of the symptoms. All of those things could play in. You mentioned robotic surgery. That's a great example. Obviously, these robots aren't doing the surgery themselves, yet, but they are assisting. When they're assisting, they are reducing complications, which means fewer readmissions and better outcomes for patients and payers. 

I think there are a lot of different opportunities to do that by blending together wearables, data collection or recording, the reporting of that data, the analysis of that data, and then, of course, coming to the conclusions from that data on what the most appropriate treatment should be. I think, in the next 25 years, we're going to see the pace of innovation in healthcare be much faster than it was the last 25 years.

Harjes: Absolutely. We've already spent a bunch of time speculating about the future and the next 25 years. Now, we're going to get back in that time machine once again and go back -- actually, a little bit more than 25 years -- to the launch of the Human Genome Project. This kicked off in 1990. It was the beginning of a tidal wave of advancement in gene sequencing. Todd, can you give us a primer, to begin with, about what that project even has to do with anything?

Campbell: DNA is like a blueprint for how our bodies work. Our understanding of how our bodies work really has been quite limited up until the 1990s, when they engaged in this massive program to go out and try and sequence the entire human genome, and be able to map it out in ways that allow us to then dive in and look for discoveries in what genes produce what proteins, and how can we manipulate those genes in ways to come up with treatments, or personalized or precision medicines, which is where we are at today. 

At the time, it was a massive undertaking. The costs that were projected to be associated with putting this project together stretched into the billions of dollars. We're talking about a decade worth of research to do something that, I suppose, now you could do with a flip of a switch. But, at the time, incredibly game-changing. Now, the fruits of that labor are being borne out. One of the most important, I think, projects undertaken in the last 25 years.

Harjes: Absolutely. That project got everything started when it came to a better understanding of the human genome. That was a publicly funded project. There were also private efforts at play here. In 1998, a company called Solexa was founded, which was eventually bought out by Illumina, another name that we talk about on the show all the time. They purchased Solexa in 2006. 

Something that Illumina's investor materials reference all the time is something called Moore's Law, which is this concept borrowed from the tech world. It has to do with the processing power of computers roughly doubling every year. It's basically a benchmark of an incredible pace for progress. Illumina references this pretty frequently, because their technology has outpaced Moore's Law, which is already held up as this standard of incredible pace for advancement. They've done even better. 

Their most recent sequencer that they launched just this year holds the promise of a $100 sequence. When you think about the fact that the Human Genome Project cost roughly $3 billion, that's an insane advancement. It gives us a really fun platform to then talk about our projections for the future. What are we going to do with all this data?

Campbell: $3 billion, and now we're talking less than $1,000. I mean, that's just amazing. It goes to show you one way how big spending upfront can spark an entire development of an industry -- an industry, obviously, now, that's resulting in the development of incredible advances in patient treatment across the number of different diseases.

Back in 2001, Francis Collins, who at the time was the director of the National Human Genome Research Institute, the people behind this project, he described the work that they were doing as a book. "A history book -- a narrative of the journey of our species through time. It's a shop manual, with an incredibly detailed blueprint for building every human cell. And it's a transformative textbook of medicine, with insights that will give healthcare providers immense new powers to treat, prevent, and cure disease." That was in 2001. 

Now, today, in 2018, we're already benefiting from the launch of gene therapies. They're revolutionary in what they're doing for patients. Luxturna -- which you and I, Kristine, have talked about on the show before -- jumps to mind as one, a gene therapy that's used to restore vision in people by replacing a gene that is mutated and faulty with one that works properly. We've also seen advances in gene therapy in cancer care. Over the course of the last year, the approval of Yescarta and Kymriah, CAR-T drugs that actually take T-cells out of patient's bodies, reengineer them, and then put them back in the body so that they can go out and find and destroy cancer. It really is quite a remarkable decade of discovery that's now proving out into these treatments that I think are going to really be life-saving for so many people. And that pace is going to accelerate, Kristine, I think.

Harjes: I agree. I also think that there are consumer applications that you will see coming out every single day at a really incredible pace. When you think about how gene sequencing stands right now, most people are getting this information through companies like 23andMe. They're mostly interested in their ancestry reports. But more and more applications are becoming available. Things like your physical fitness, or things like dietary responses in your body that maybe you didn't know about until you were able to receive this data. 

Illumina actually founded a company called Helix. Its whole goal is to create this central repository where it has your sequenced genome. Then, there are apps layered on top of it, where if you want that information about, maybe, genetic information about how you should restrict your diet or what have you, that could be an application that sits on top of that central repository, and you can access it to get the information that you want. 

I think there's an even broader point to be made here about access to data. Right now, it's kind of tough to get your medical records. Information about your body that's so, so personal is locked away in these not-interoperable medical records. It feels like you don't really own or have access to your own information. Genetic information is just one component of that. I see a broader trend toward democratization of data. I think, in healthcare, people will demand it at a certain point. They will demand that they have ownership of their information, and that they have convenient access to their data. 

We're seeing this a little bit already with stuff like the iPhone's Health app. We're seeing more and more companies that are interested in fixing the EHR space and making it so that your medical records are able to talk from one doctor's office to another. But I think we still have a long way to go.

Campbell: We absolutely have a long way to go. I want to say it's kind of embarrassing, given the access that we have to data right now in our personal lives, and how easily we can share that with everybody, both intentionally and unintentionally, right, Kristine? I think, one of the things that we're going to have to try and figure out is almost some sort of a blockchain-type system for allowing that access to be verified, and then freeing all that information to flow without having to have, say, a HIPAA release signed by every person who may view it. You could go into a blockchain and say, "There's a HIPAA release here, it's obviously been approved for everybody," and then being able to share that across any kind of system to try and come up with some of these. I have a hard time believing, Kristine, that that's not where we're heading. 

We're going to be, eventually, in a world where everybody is going to have their genomic profiles somewhere; that we'll be able to analyze that genomic profile for early intervention, preventative or predictive. And, all of the data is going to be able to be leveraged by AI in ways that allow us to make sure that the right treatment is getting to the right person, at the right time. It truly is going to be a pretty exciting time. I think that genomics, and the work that was done on the Human Genome Project going back all the way into the early 90s when -- The Motley Fool was just being born -- I think that is what's facilitating, really, all of this. 

Harjes: And things will move slowly. They'll continue to be frustrating. By the time we have interoperable medical records figured out, there will be some new advancement that's proliferated the other sectors, probably, and we'll be exasperated that healthcare hasn't caught up. But it's so apparent that the wheels of progress are continuing to turn. As investors, we should look to the companies that have a great vision for the future and are making progress toward it. 

Campbell: Absolutely. 100% agree, Kristine. We mentioned a couple of them on the show already. Teladoc is one, in telehealth, earlier on in the show. Apple's doing some pretty exciting things. Illumina is obviously a very intriguing company, and so is Intuitive Surgical. All of those are companies that have me thinking they can benefit from multi-decade trends.

Harjes: Yeah. It's one of the privileges of being an investor -- you get to be a part of this in some small way. Watching it is a lot of fun, too. 

As always, people on the program may have interests in the stocks that they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. Today's show is produced by Austin Morgan. For Todd Campbell, I'm Kristine Harjes. Thanks for listening and Fool on!

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Kristine Harjes owns shares of AAPL. Todd Campbell owns shares of AMZN, AAPL, and FB. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends AMZN, AAPL, FB, Illumina, and ISRG. The Motley Fool has the following options: long January 2020 $150 calls on AAPL and short January 2020 $155 calls on AAPL. The Motley Fool recommends Teladoc. The Motley Fool has a disclosure policy.

  • A former GE exec who trained new managers found that almost all of them were making the same mistake
    Business Insider

    A former GE exec who trained new managers found that almost all of them were making the same mistake

    Beth Comstock is the former vice chair of General Electric. Comstock would hand out "permission slips" authorizing employees to take risks — but she also said it's important for people to stop hiding behind their excuses. Beth Comstock doesn't tolerate excuses.

  • Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'
    Yahoo Finance

    Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'

    Billionaire investor and philanthropist Ken Langone, the founder of The Home Depot (HD) and chairman of Invemed Associates, argued that there’s some “big time” structural problems in the market right now. Because if we are on a trajectory of raising rates that means, and if it keeps going that way and I don’t know how high it will go, and it keeps going that way then all the sudden the guy who bought those bonds is going to be looking at a fairly decent loss,” Langone said.

  • Intel restructures manufacturing organization
    American City Business Journals

    Intel restructures manufacturing organization

    Chip giant Intel is restructuring its technology and manufacturing business group as it chases more connected device markets and grapples with delays on its next chip generation. In a memo to employees, reviewed by the Business Journal, Group President and Chief Engineering Officer Murthy Renduchintala described splitting the technology and manufacturing business into three groups. The three new groups are technology development, manufacturing and operations and global supply chain.

  • At Facebook, public funds join push to remove Zuckerberg as chairman

    At Facebook, public funds join push to remove Zuckerberg as chairman

    State treasurers from Illinois, Rhode Island and Pennsylvania, and New York City Comptroller Scott Stringer, co-filed the proposal. A similar shareholder proposal seeking an independent chair was defeated in 2017 at Facebook, where Zuckerberg's majority control makes outsider resolutions effectively symbolic.

  • Boeing (BA) Q3 Earnings Preview: What to Expect

    Boeing (BA) Q3 Earnings Preview: What to Expect

    Boeing (BA) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 24, 2018, might help the stock move higher if these key numbers are better than expectations.

  • Illumina (ILMN) Gains As Market Dips: What You Should Know

    Illumina (ILMN) Gains As Market Dips: What You Should Know

    This has lagged the Medical sector's loss of 2.89% and the S&P 500's loss of 3.08% in that time. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $825.07 million, up 15.56% from the year-ago period. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

  • Steven Mnuchin, Who Sat on Sears' Board for Years, Could Impact the Pensions of Thousands of Workers

    Steven Mnuchin, Who Sat on Sears' Board for Years, Could Impact the Pensions of Thousands of Workers

    Long before he was Secretary of the Treasury, Steven Mnuchin was a student at Yale University. One of those was Eddie Lampert. Lampert, of course, is the recently departed CEO of Sears Holdings, which filed for Chapter 11 bankruptcy Monday.

  • Employee Accused of Urinating on Production Line at Food Processing Facility
    WTKR - Norfolk

    Employee Accused of Urinating on Production Line at Food Processing Facility

    Smithfield Foods, Inc. said in a statement Tuesday that it disposed of more than 50,000 pounds of product after reports of an employee urinating at his station at the company’s processing facility in Virginia.

  • Pfizer to cut around 2 percent of jobs through early next year

    Pfizer to cut around 2 percent of jobs through early next year

    U.S. drugmaker Pfizer Inc (PFE.N) plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities. Pfizer has around 90,000 employees worldwide. Shares of Pfizer were up 1.8 percent at $44.70 in early afternoon trading on the New York Stock Exchange.

  • Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade
    Market Realist

    Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade

    Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade Credit Suisse’s downgrade Today, CNBC reported that Credit Suisse downgraded Home Depot (HD) stock from “outperform” to “neutral.” Credit Suisse lowered its price target from $222.00 to $204.00

  • Business

    Jim Cramer: How These Five Tech Powerhouses Keep Coming Back

    if FAANG doesn't come back. Netflix added 1,09 million domestic subs which exceeded the 673,000 consensus, and internationally the company added a staggering 5.87 million subs versus the 4.46 million the analysts were hoping for. Netflix now has 130 million paid customers and it predicts another 9 million people will join in the fourth quarter.

  • Here's the Average Social Security Benefit for 2019
    Motley Fool

    Here's the Average Social Security Benefit for 2019

    Millions of seniors collect Social Security, and without it, they'd be underwater on their bills. At present, the average retiree gets $1,422 a month in Social Security benefits. There's a world of misinformation surrounding Social Security, and perhaps one of the most detrimental myths out there is the notion that the program is enough to sustain seniors by itself.

  • Legal pot in Canada putting pressure on US
    Yahoo Finance Video

    Legal pot in Canada putting pressure on US

    Canada’s moves to legalize recreational marijuana could have major impacts on the US. Yahoo Finance’s Alexis Christoforous speaks with Alexis Keenan about the state of legalization in this country.

  • 3 Stocks for Warren Buffett Fans
    Motley Fool

    3 Stocks for Warren Buffett Fans

    Warren Buffett has no shortage of acolytes, and it's easy to see why. The Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) chief and founder has made thousands of early investors in his conglomerate rich as the parent of businesses like GEICO car insurance and Burlington Northern Santa Fe railroad has posted average annual returns of 20% over the last 50 years, crushing the market. Buffett has never gotten too big for his britches, however.

  • IBM disappoints, more Facebook accusations, Apple apologizes
    Yahoo Finance

    IBM disappoints, more Facebook accusations, Apple apologizes

    Here’s a look at some of the companies the Yahoo Finance team will be watching for you today. IBM investors aren’t thrilled with the latest earnings report. The company posted a beat on earnings but revenue missed. CEO Ginni Rometty says the results show

  • Housing Stocks Tumble Midday; Home Depot Dents Dow

    Housing Stocks Tumble Midday; Home Depot Dents Dow

    Investing.com - Home Depot (NYSE:HD) and other housing-leveraged stocks fell in midday trading following disappointing data on home construction. Home Depot fell about 4.2% at 12:08 PM ET (16:08 GMT) and was a drag on the Dow Jones Industrial Average

  • Where Will NVIDIA Be in 5 Years?
    Motley Fool

    Where Will NVIDIA Be in 5 Years?

    At one time, NVIDIA (NASDAQ: NVDA) floated under the radar in the technology sector. Its graphics processing units (GPUs) were then niche tech products that appealed mainly to graphic artists and hardcore PC gamers, but that all changed over the last

  • Better Buy: The Home Depot, Inc. vs. Lowe's
    Motley Fool

    Better Buy: The Home Depot, Inc. vs. Lowe's

    Home Depot (NYSE: HD) and Lowe's (NYSE: LOW) have helped countless homeowners increase the value of their homes. They've also made many investors rich. With their shares having soared 879% and 484%, respectively, over the past decade, Home Depot and Lowe

  • GE to pay penalty if falls short of French job pledges: ministry

    GE to pay penalty if falls short of French job pledges: ministry

    General Electric's new CEO told France's finance minister on Wednesday that it would stick to his predecessor's French job pledges or pay a penalty, the Finance Ministry said. Former CEO John Flannery warned French Finance Minister Bruno Le Maire in June that the target was "out of reach", and the government raised the possibility of fines worth 50,000 euros ($57,570) for each job not created. GE's new CEO Larry Culp, who took up his post at the start of the month, told Le Maire in a meeting on Wednesday that France remained a strategic country for the company, the ministry said in statement.

  • Kinder Morgan Canada's profit surges on TransMountain sale

    Kinder Morgan Canada's profit surges on TransMountain sale

    The company said on Wednesday it expects to return about C$1.2 billion ($921.5 million) or C$11.40 per restricted voting share from the sale to its shareholders. Its parent, U.S.-based Kinder Morgan Inc, closed the sale of the controversial Trans Mountain pipeline to the Canadian government for C$4.5 billion in August. Kinder Morgan Canada said net income rose to C$1.35 billion in the three months ended Sept. 30, from C$42.4 million, a year earlier.

  • Business

    Berkshire Hathaway shares look really cheap using Warren Buffett's own method of valuing stocks

    Companies pay investors dividends but they also retain some of their earnings. Over time, companies invest these retained earnings at a higher rate of return and that ultimately boosts their share prices, benefiting their investors. J.P. Morgan analyst Sarah DeWitt calculates that Berkshire's share of undistributed earnings from its stock portfolio is $12 billion, or about $5.19 per Berkshire Class B share.

  • Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For

    Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For

    Advanced Micro Devices (AMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 24, 2018, might help the stock move higher if these key numbers are better than expectations.

  • Business

    Kinder Morgan's Q3 Earnings Preview

    Kinder Morgan (NYSE: KMI) will be releasing its next round of earnings Wednesday. For all of the relevant information, here is your guide for the Q3 earnings announcement. Earnings and Revenue Analysts expect Kinder Morgan earnings of 21 cents per share

  • Walmart will save $20 million annually on floor wax

    Walmart will save $20 million annually on floor wax

    Walmart Inc. has found a new way to save millions of dollars: Switch the floor wax it uses in its stores. According to the retail giant’s Chief Financial Officer Brett Biggs, Walmart (WMT)  switched to a new floor wax that’s both cheaper and more effective, reducing the number of times the floors have to be buffed. “That one change in floor wax will save us over $20 million a year,” he said, according to a FactSet transcript of the company’s Tuesday investment community meeting.

  • Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves

    Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves

    After two consecutive off-the-mark quarters, falling short of its own forecasts for subscriber growth, Netflix Inc. hopes to put an end to the big swings in its stock price with some changes to its accounting. Three months ago, Netflix reported weaker-than-expected subscriber growth, sending its stock tumbling about 12% in the next trading day. From last quarter: Is Netflix stock falling down a mountain, or just tripping over a molehill?